A Phase 1 Study of ADI-001 in B Cell Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Marginal Zone Lymphoma
Related studies linked through entity extraction aliases.
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of Acalabrutinib and Tafasitamab in MZL Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2